Lui et al. showed that the combination of crizotinib with cisplatin, which is known as nonimmunogenic cell death-inducing chemotherapy in NSCLC cells in vitro and in vivo, can lead to an increase in T lymphocyte infiltration and the expression of PD-1 and PD-L1. Here, CD274 is linked to non-small cell lung carcinoma.